PRODUCT SAFETY AND SATISFACTION
TEOSYAL ® PURESENSE REDENSITY 2
With over 9 years of expertise and more than 2 millions of injections worldwide1,2, Teoxane’s TEOSYAL ® PURESENSE REDENSITY 2 is the 1st & only one hyaluronic acid gel designed for the treatment of under eye hollows 2-4
TEOSYAL ® PURESENSE REDENSITY 2, the Hyaluronic Acid filler with a rheological profile specifically designed to treat infraorbital hollows3:
LOW HYGROSCOPY
for immediate and natural correction 4
LOW PRESSURE ON TISSUES
For a decreased risk of oedema 4
GOOD SPREADABILITY
For a better postionning of the gel 4
GOOD TISSUE INTEGRATION & ACTION ON SKIN THICKNESS
For hydration and improvement of the ageing skin 22
FILLER CHARACTERISTICS FOR THE UNDER EYE REGION
In a recent international survey, practitioners reported that the most important outcomes of TEOSYAL® PURESENSE REDENSITY 2 for their patients include:
- Natural-looking results 16
-Immediate results 16
-Youthful looks 16
-Up to 12 months duration 14
PROVEN SAFETY OVER YEARS
TEOSYAL® PURESENSE REDENSITY 2 GOOD SAFETY PROFILE
Annual average of 21:
•Less than 2 ADVERSE REACTIONS per 10,000 sold syringes
•Less than 2 cases of TYNDALL EFFECT per 100,000 sold syringes
•Less than 1.5 cases of SKIN OEDEMA per 10,000 sold syringes
TEOSYAL ® PURESENSE REDENSITY 2 SAFETY RECOGNIZED IN A CLINICAL TRIAL2
Most side effects reported were mild, temporary and correctable2
During the clinical trial
• Mainly mild and transient post-injection reactions
• No blue discoloration / Tyndall effect (after 1 month)
• No need for hyaluronidase
• No unpleasant malar swelling
* Multicentric and international study: 2012/2013. 33 practitioners,151 patients (86% of women and 14% of men).
Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation.
Indications: 93% of patients were injected in the tear trough area.
Adverse event included Swelling (11,6%), Bruising(10,7%), Redness (6,3%), Blue discoloration (0,9%), Other (1,8%)
Reducing the risk of adverse event in the under eye region
One of the most common adverse events in the scientific literature is Tyndall effect which is a blue gray discoloration under the eye. […] if you're using REDENSITY 2 and you're injecting supraperiosteally, you shouldn't be having this risk
An easy injection for a reliable practice2
TEOSYAL RHA® 4
SOFT & DYNAMIC VOLUMIZING IN THE MID CHEEK
As midface volume deficit increases, tear trough severity increases significantly. Adding volume to the midface using hyaluronic acid dermal filler can help reduce the appearance of tear troughs.
Therefore, midface volume deficit is adequately treated first prior to the infraorbital hollow.12
TEOSYAL RHA® 4, the volumizer designed to provide soft volume enhancement and facial dynamism to facilitate natural-looking facial expressions 5,6,19,20
#Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL
TEOSYAL RHA® 4 rheological profile6
LOW BDDE TO GET CLOSER TO NATURAL HA
HIGH STRENGTH
GOOD STRECH
ABILITY TO MAINTAIN ITS STRUCTURE
UP TO 18 MONTHS DURATION 20
BDDE = 1,4-Butanediol diglycidyl ether
MoD= Degree of Modification
HMW= High Molecular Weight
References
1.Teoxane internal data source. Teosyal Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes
2.Berguiga et al. Orbit, 2017; 36(1):22-26.
3.TEOSYAL ® PURESENSE REDENSITY 2 – instruction for use
4.TEOXANE R&D report RDRE 2023. Data on File. Physical analysis of HA fillers intended for infraborbital uses. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. . “
5.TEOSYAL RHA® 4 – instruction for use
6.RDRE 2015 - Rheological analysis of Volumizers _ Ultra Deep_RHA4_Lyft_Voluma
7. Michaud et al. J Cosmet Dermatol. 2015; 14(1): 9–21
8. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o
9. Teoxane data source TEO-RHA-1902 Injection Guidelines
10. Funt. J Clin Aesthet Dermatol. 2011; 4(12):32-63
11. Bravo et al. J Clin Aesthet Dermatol. 2015; 8(6):30-5
12. Glaser et al. Dermatol Surg 2018; 44:1547-1554
13. Beleznay et al. Dermatol Surg. 2015; 41:1097-1117
14. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide
15. Ramanadham et al. Plast Reconstr Surg. 2015; 136:49S-55S
16.Teoxane Worldwide Survey "Periorbital Treatments in Clinics" by 180 injectors, June 2020
17. Cotofana et al. Facial Plast Surg. 2016; 32:253-260
18. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011
19. Kaufman-Janette et al. J Cosmet Dermatol. 2019; doi: 10.1111/jocd.1310
20. Rzany et al. Dermatol Surg; 2019; 45(10):1304-1314
21. TEOXANE Post-Marketing Surveillance from 2016 to 2020-Q3
22. Data on file 2020. Syneos study report 7010664.SA.259
23. Sharad. J Cutan Aesthet Surg. 2012; 5:229238
24. Sadick et al. Cosmet Dermatol. 2007;6(4):218-22
25. The properties of ingredients derive from data communicated by the raw material manufacturers
26.Efficacy study. Results measured after 28 days of use
* REDENSITY 2 = TEOSYAL® PureSense REDENSITY 2
# Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL
